Scienture Holdings, Inc. (NASDAQ: SCNX) Stock Competitors & Peer Comparison
See SCNX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SCNX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SCNX | $0.31 | +0.10% | 12.7M | -0.15 | -$2.10 | N/A |
| RPRX | $58.41 | -0.88% | 25.9B | 11.13 | $5.25 | +1.59% |
| CORT | $110.29 | -3.98% | 11.9B | 315.11 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $66.88 | -2.21% | 5.9B | 477.71 | $0.14 | N/A |
| KNSA | $77.24 | -2.63% | 5.9B | 85.82 | $0.90 | N/A |
| PBH | $44.97 | -3.23% | 2.1B | 10.17 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $22.55 | -5.77% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
SCNX vs RPRX Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while RPRX trades at $58.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas RPRX's P/E ratio is 11.13. In terms of profitability, SCNX's ROE is -0.54%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SCNX is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
SCNX vs CORT Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CORT has a market cap of 11.9B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CORT trades at $110.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CORT's P/E ratio is 315.11. In terms of profitability, SCNX's ROE is -0.54%, compared to CORT's ROE of +0.08%. Regarding short-term risk, SCNX is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
SCNX vs WBA Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas WBA's P/E ratio is -1.64. In terms of profitability, SCNX's ROE is -0.54%, compared to WBA's ROE of -0.57%. Regarding short-term risk, SCNX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
SCNX vs LQDA Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while LQDA trades at $66.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas LQDA's P/E ratio is 477.71. In terms of profitability, SCNX's ROE is -0.54%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, SCNX is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
SCNX vs KNSA Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, KNSA has a market cap of 5.9B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while KNSA trades at $77.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas KNSA's P/E ratio is 85.82. In terms of profitability, SCNX's ROE is -0.54%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, SCNX is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
SCNX vs PBH Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, PBH has a market cap of 2.1B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while PBH trades at $44.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas PBH's P/E ratio is 10.17. In terms of profitability, SCNX's ROE is -0.54%, compared to PBH's ROE of +0.09%. Regarding short-term risk, SCNX is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
SCNX vs HROWL Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas HROWL's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, SCNX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
SCNX vs LTGO Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, LTGO has a market cap of 1.4B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while LTGO trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas LTGO's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to LTGO's ROE of N/A. Regarding short-term risk, SCNX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check LTGO's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
SCNX vs HROWM Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas HROWM's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, SCNX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
SCNX vs HELP Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, HELP has a market cap of 766.7M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while HELP trades at $12.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas HELP's P/E ratio is -2.97. In terms of profitability, SCNX's ROE is -0.54%, compared to HELP's ROE of -0.71%. Regarding short-term risk, SCNX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
SCNX vs SVA Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas SVA's P/E ratio is -5.68. In terms of profitability, SCNX's ROE is -0.54%, compared to SVA's ROE of -0.01%. Regarding short-term risk, SCNX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
SCNX vs CUVL Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CUVL has a market cap of 297.5M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CUVL trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CUVL's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to CUVL's ROE of N/A. Regarding short-term risk, SCNX is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
SCNX vs CELG-RI Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CELG-RI has a market cap of 242.7M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, SCNX is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
SCNX vs HITI Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while HITI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas HITI's P/E ratio is -7.57. In terms of profitability, SCNX's ROE is -0.54%, compared to HITI's ROE of -0.36%. Regarding short-term risk, SCNX is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check HITI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
SCNX vs CTOR Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CTOR has a market cap of 106M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CTOR trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CTOR's P/E ratio is -2.43. In terms of profitability, SCNX's ROE is -0.54%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, SCNX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
SCNX vs ATLN Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas ATLN's P/E ratio is -0.68. In terms of profitability, SCNX's ROE is -0.54%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, SCNX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check ATLN's competition here
Stablecoin Development Corp. (AMEX: SDEV)
SCNX vs SDEV Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, SDEV has a market cap of 52.2M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while SDEV trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas SDEV's P/E ratio is -0.18. In terms of profitability, SCNX's ROE is -0.54%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, SCNX is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
SCNX vs RAD Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas RAD's P/E ratio is -0.05. In terms of profitability, SCNX's ROE is -0.54%, compared to RAD's ROE of +2.76%. Regarding short-term risk, SCNX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
SCNX vs GLTO Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas GLTO's P/E ratio is -1.78. In terms of profitability, SCNX's ROE is -0.54%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, SCNX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
SCNX vs NSRX Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, NSRX has a market cap of 29.7M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while NSRX trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas NSRX's P/E ratio is -4.78. In terms of profitability, SCNX's ROE is -0.54%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, SCNX is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
SCNX vs SCYX Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, SCYX has a market cap of 28M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while SCYX trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas SCYX's P/E ratio is -1.30. In terms of profitability, SCNX's ROE is -0.54%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, SCNX is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
SCNX vs COSM Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, COSM has a market cap of 17.9M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while COSM trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas COSM's P/E ratio is -0.45. In terms of profitability, SCNX's ROE is -0.54%, compared to COSM's ROE of -1.19%. Regarding short-term risk, SCNX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
SCNX vs BFRI Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, BFRI has a market cap of 16.9M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while BFRI trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas BFRI's P/E ratio is -2.40. In terms of profitability, SCNX's ROE is -0.54%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, SCNX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
SCNX vs CNSY Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CNSY has a market cap of 14M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CNSY trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CNSY's P/E ratio is -0.48. In terms of profitability, SCNX's ROE is -0.54%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, SCNX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
SCNX vs BFRIW Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, BFRIW has a market cap of 11.4M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, SCNX's ROE is -0.54%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, SCNX is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check BFRIW's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
SCNX vs CJJD Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CJJD's P/E ratio is -0.46. In terms of profitability, SCNX's ROE is -0.54%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, SCNX is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
SCNX vs SSY Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas SSY's P/E ratio is -2.86. In terms of profitability, SCNX's ROE is -0.54%, compared to SSY's ROE of -0.09%. Regarding short-term risk, SCNX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
SCNX vs POM Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while POM trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas POM's P/E ratio is -0.16. In terms of profitability, SCNX's ROE is -0.54%, compared to POM's ROE of +0.16%. Regarding short-term risk, SCNX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
SCNX vs BGMS Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, BGMS has a market cap of 5.2M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while BGMS trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas BGMS's P/E ratio is -0.26. In terms of profitability, SCNX's ROE is -0.54%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, SCNX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
SCNX vs PAVS Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while PAVS trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas PAVS's P/E ratio is -0.05. In terms of profitability, SCNX's ROE is -0.54%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, SCNX is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check PAVS's competition here
Eocene Ltd. (NASDAQ: EOCN)
SCNX vs EOCN Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, EOCN has a market cap of 3.5M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while EOCN trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas EOCN's P/E ratio is -0.24. In terms of profitability, SCNX's ROE is -0.54%, compared to EOCN's ROE of N/A. Regarding short-term risk, SCNX is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check EOCN's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
SCNX vs MDVL Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas MDVL's P/E ratio is -0.05. In terms of profitability, SCNX's ROE is -0.54%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, SCNX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
SCNX vs ATNFW Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas ATNFW's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, SCNX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
SCNX vs BGMSP Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, SCNX's ROE is -0.54%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, SCNX is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
SCNX vs AZNH Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas AZNH's P/E ratio is 38.35. In terms of profitability, SCNX's ROE is -0.54%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, SCNX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
SCNX vs LFLYW Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, SCNX's ROE is -0.54%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, SCNX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
SCNX vs PRPH Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, PRPH has a market cap of 175.2K. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas PRPH's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, SCNX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
SCNX vs CPD Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, CPD has a market cap of 0. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas CPD's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to CPD's ROE of N/A. Regarding short-term risk, SCNX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check CPD's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
SCNX vs ESRX Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas ESRX's P/E ratio is 10.69. In terms of profitability, SCNX's ROE is -0.54%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, SCNX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
SCNX vs OREX Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, OREX has a market cap of 0. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas OREX's P/E ratio is -0.14. In terms of profitability, SCNX's ROE is -0.54%, compared to OREX's ROE of -0.54%. Regarding short-term risk, SCNX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check OREX's competition here
Shire plc (NASDAQ: SHPG)
SCNX vs SHPG Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas SHPG's P/E ratio is 11.35. In terms of profitability, SCNX's ROE is -0.54%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, SCNX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for SCNX.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
SCNX vs IPXL Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas IPXL's P/E ratio is -10.11. In terms of profitability, SCNX's ROE is -0.54%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, SCNX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check IPXL's competition here
POZEN Inc. (NASDAQ: POZN)
SCNX vs POZN Comparison September 2026
Scienture Holdings, Inc. (NASDAQ: SCNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNX stands at 12.7M. In comparison, POZN has a market cap of 0. Regarding current trading prices, SCNX is priced at $0.31 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNX currently has a P/E ratio of -0.15, whereas POZN's P/E ratio is N/A. In terms of profitability, SCNX's ROE is -0.54%, compared to POZN's ROE of +0.61%. Regarding short-term risk, SCNX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for SCNX.Check POZN's competition here